KLCM
RNTX

KG&L Capital Management’s Rein Therapeutics RNTX Stock Holding History

KG&L Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,000
Closed -$20.9K – 219
2025
Q4 		$20.9K Hold
18,000
– – 0.01% 219
2025
Q3 		$20.6K Hold
18,000
– – 0.01% 214
2025
Q2 		$25.2K Hold
18,000
– – 0.01% 187
2025
Q1 		$31.9K Hold
18,000
– – 0.01% 193
2024
Q4 		$41.4K Buy
18,000
+5,000
+38% +$15.1K 0.01% 184
2024
Q3 		$46K Buy
+13,000
New +$34.8K 0.01% 189

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

KG&L Capital Management's RNTX Position: Q1 2026 in Review

KG&L Capital Management sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 18,000 shares — an estimated $20.9K sold.

KG&L Capital Management first reported a position in RNTX in Q3 2024 and held it in 6 quarters. The position peaked at $46K in Q3 2024. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • KG&L Capital Management reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
  • KG&L Capital Management sold 18,000 Rein Therapeutics shares in Q1 2026, an estimated $20.9K.
  • KG&L Capital Management first reported a position in Rein Therapeutics in Q3 2024 and held it in 6 quarters.
  • KG&L Capital Management's Rein Therapeutics position peaked at $46K in Q3 2024.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on KG&L Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.